Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan
Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan
复制标题
DOI：
10.1200/jco.2007.15.4278
复制
发表时间：
2008-07-01
影响因子：
45.3
通讯作者：
Kinoshita, Tomohiro
中科院分区：
文献类型：
--
作者：
Shimada, Kazuyuki;Matsue, Kosei;Kinoshita, Tomohiro
PurposeTo评估含利妥昔单抗化疗的血管内大B细胞淋巴瘤（IVLBCL）的安全性和有效性。患者和方法我们回顾性分析了106例（59名男性，47名女性）IVLBCL患者，他们在1994年至2007年期间接受利妥昔单抗（R-化疗，n = 49）或不接受利妥昔单抗（化疗，n = 57）。患者的中位年龄为67岁（范围：34 - 84岁）。国际预后指数高-中/高97%的patients.ResultsThe完全缓解率较高的患者在R-化疗组（82%）比化疗组（51%; P = .001）。存活患者的中位随访时间为18个月（范围：1至95个月）。诊断后2年，R-化疗组患者的无进展生存期（PFS）和总生存期（OS）率（PFS，56%; OS，66%）显著高于化疗组患者（PFS，27%，P = 0.001; OS，46%，P = 0.01）。多变量分析显示，利妥昔单抗的使用与PFS（风险比[HR]，0.45; 95%CI，0.25 - 0.80; P = 0.006）和OS（HR，0.42; 95%CI，0.21 - 0.85; P = 0.016）有利相关。治疗相关的死亡观察到三名患者（6%）谁接受R-化疗和五名患者（9%）谁接受chemotherapy.ConclusionOur数据表明，利妥昔单抗时代IVLBCL患者的临床结局改善。未来对含利妥昔单抗的化疗进行前瞻性研究是必要的。
PurposeTo evaluate the safety and efficacy of rituximab-containing chemotherapies for intravascular large B-cell lymphoma (IVLBCL).Patients and MethodsWe retrospectively analyzed 106 patients (59 men, 47 women) with IVLBCL who received chemotherapy either with rituximab (R-chemotherapy, n = 49) or without rituximab (chemotherapy, n = 57) between 1994 and 2007 in Japan. The median patient age was 67 years (range, 34 to 84 years). The International Prognostic Index was high-intermediate/high in 97% of patients.ResultsThe complete response rate was higher for patients in the R-chemotherapy group (82%) than for those in the chemotherapy group (51%; P = .001). The median duration of follow-up for surviving patients was 18 months (range, 1 to 95 months). Progression-free survival (PFS) and overall survival (OS) rates at 2 years after diagnosis were significantly higher for patients in the R-chemotherapy group (PFS, 56%; OS, 66%) than for patients in the chemotherapy group (PFS, 27% with P = .001; OS, 46% with P = 0.01). Multivariate analysis revealed that the use of rituximab was favorably associated with PFS (hazard ratio [HR], 0.45; 95% CI, 0.25 to 0.80; P = .006) and OS (HR, 0.42; 95% CI, 0.21 to 0.85; P = .016). Treatment-related death was observed in three patients (6%) who received R-chemotherapy and in five patients (9%) who received chemotherapy.ConclusionOur data suggest improved clinical outcomes for patients with IVLBCL in the rituximab era. Future prospective studies of rituximab-containing chemotherapies are warranted.